Standout Papers

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-patholo... 1988 2026 2000 2013 8.4k
  1. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. (1992)
    Andrew Hughes, S. E. Daniel et al. Journal of Neurology Neurosurgery & Psychiatry
  2. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. (1988)
    W R Gibb, Andrew J. Lees Journal of Neurology Neurosurgery & Psychiatry
  3. AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY (1991)
    Julian Fearnley, Andrew J. Lees Brain
  4. Second consensus statement on the diagnosis of multiple system atrophy (2008)
    S. Gilman, Gregor K. Wenning et al. Neurology
  5. Parkinson's disease (2009)
    Andrew J. Lees, John Hardy et al. The Lancet
  6. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation (2008)
    Jiayi Li, Elisabet Englund et al. Nature Medicine
  7. Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease (1989)
    David T. Dexter, Christopher Carter et al. Journal of Neurochemistry
  8. What features improve the accuracy of clinical diagnosis in Parkinson's disease (1992)
    Andrew Hughes, Yoav Ben‐Shlomo et al. Neurology
  9. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia (1994)
    David T. Dexter, Andrew J. Lees et al. Annals of Neurology
  10. ALTERATIONS IN THE LEVELS OF IRON, FERRITIN AND OTHER TRACE METALS IN PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES AFFECTING THE BASAL GANGLIA (1991)
    David T. Dexter, A. Carayon et al. Brain
  11. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service (2002)
    Andrew Hughes, Susan E. Daniel et al. Brain
  12. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system (2005)
    Philippe Rémy, M Doder et al. Brain
  13. Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease (2001)
    Andrew Hughes, Susan E. Daniel et al. Neurology
  14. COGNITIVE DEFICITS IN THE EARLY STAGES OF PARKINSON'S DISEASE (1983)
    Andrew J. Lees, Eileen Smith Brain
  15. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin (2006)
    Elisa Greggio, Shushant Jain et al. Neurobiology of Disease
  16. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial (2017)
    Dilan Athauda, Kate Maclagan et al. The Lancet
  17. A common LRRK2 mutation in idiopathic Parkinson's disease (2005)
    William P. Gilks, Patrick M. Abou‐Sleiman et al. The Lancet
  18. Parkinson's Disease Society Brain Bank, London: overview and research. (1993)
    S. E. Daniel, Andrew J. Lees PubMed
  19. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism (2005)
    David R. Williams, Rohan de Silva et al. Brain
  20. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease (2009)
    José Brás, Emma Deas et al. Brain
  21. Meta‐analysis of early nonmotor features and risk factors for Parkinson disease (2012)
    Alastair J. Noyce, Jonathan P. Bestwick et al. Annals of Neurology
  22. Blood-based NfL (2017)
    Oskar Hansson, Shorena Janelidze et al. Neurology
  23. Visual dysfunction in Parkinson’s disease (2016)
    Rimona S. Weil, Anette Schrag et al. Brain
  24. Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease (2019)
    Eduardo De Pablo‐Fernández, Andrew J. Lees et al. JAMA Neurology
  25. Medical, surgical, and physical treatments for Parkinson's disease (2024)
    Thomas Foltynie, Verónica Bruno et al. The Lancet

Immediate Impact

6 by Nobel laureates 25 from Science/Nature 189 standout
Sub-graph 1 of 15

Citing Papers

Phase I trial of hES cell-derived dopaminergic neurons for Parkinson’s disease
2025 StandoutNature
Parkinson's disease
2021 Standout
201 intermediate papers

Works of Andrew J. Lees being referenced

Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial
2018
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
2017 Standout
and 155 more

Author Peers

Author Last Decade Papers Cites
Andrew J. Lees 55031 20679 10784 11078 728 72.6k
Anthony E. Lang 56088 24236 10518 7852 889 74.7k
David J. Brooks 30960 19605 10468 9723 716 59.9k
Joseph Jankovic 43664 18831 5746 6488 804 57.9k
Yves Agid 31073 25204 8135 6299 603 54.2k
Werner Poewe 42303 13727 6638 6316 679 56.2k
C. D. Marsden 33459 21920 16178 5111 717 65.7k
Glenda M. Halliday 29271 13334 8666 13115 645 49.5k
K. A. Jellinger 21187 11000 9446 13152 1.0k 47.3k
Dag Aarsland 24797 5474 4160 9337 641 43.1k
Heiko Braak 25978 16106 13515 31701 358 66.6k

All Works

Loading papers...

Rankless by CCL
2026